\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 study, both evaluating brelovitug for the treatment of chronic hepatitis delta virus (HDV). Achievement of these milestones confirms the expected timing of topline 24-week data in the second half of 2026. AZURE-1 and AZURE-4 together will form the basis of Mirum\u2019s U.S. BLA submission for brelovitug, which has received Breakthrough Therapy designation from the FDA for the treatment of chronic HDV infection.<\/p>\n
\nBrelovitug is being developed for HDV, the most severe form of viral hepatitis, and a disease with no approved therapies in the U.S. HDV occurs in people already infected with hepatitis B virus (HBV) and is associated with rapid progression to liver fibrosis, cirrhosis, liver cancer, and liver-related death.<\/p>\n
\n\u201cThe completion of AZURE-1 enrollment and AZURE-4 screening represent important execution milestones as we advance brelovitug through the Phase 3 AZURE program,\u201d said Joanne Quan, M.D., Chief Medical Officer at Mirum Pharmaceuticals. \u201cWe look forward to reporting interim data from AZURE-1 in the second quarter and topline results from AZURE-1 and AZURE-4 in the second half of 2026. Both studies are evaluating a composite endpoint of virologic response and ALT normalization at 24 weeks, aligned with FDA guidance for accelerated approval in HDV, and building on the strong antiviral activity observed in our Phase 2 study.\u201d<\/p>\n
\n\u201cHDV is an aggressive disease that progresses quickly and leaves patients with very limited treatment options,\u201d said Tatyana Kushner, M.D., MSCE, Associate Professor of Medicine, Division of Gastroenterology and Hepatology at Weill Cornell Medicine. \u201cHaving a well-tolerated single-agent therapy that achieves viral suppression and improves liver inflammation is critical for patients with HDV, and the progress of these Phase 3 studies brings us closer to potentially delivering a new therapy to patients in urgent need.\u201d<\/p>\n
\nTopline data from AZURE-1 and AZURE-4 are expected in 2H 2026, with a potential BLA submission and launch in the U.S. in 2027.<\/p>\n
About Brelovitug<\/b><\/p>\n
\nBrelovitug is an investigational, highly potent, pan-genotypic, fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) on both the chronic hepatitis delta virus (HDV) and the hepatitis B virus (HBV). Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles. Brelovitug has FDA Breakthrough Therapy designation for the treatment of chronic HDV infection and PRIME and Orphan designations from the European Medicines Agency. In the Phase 2 study, brelovitug demonstrated strong antiviral activity in HDV, achieving a 100% HDV RNA response, along with improvements in liver enzyme levels and a favorable safety profile, with the most common adverse event being injection-site erythema. Mirum owns worldwide rights to brelovitug.<\/p>\n
About the AZURE Clinical Program<\/b><\/p>\n
\nThe AZURE program is a global, registrational Phase 3 clinical development program evaluating brelovitug for the treatment of chronic hepatitis delta virus (HDV). The program includes multiple open-label studies designed to assess the primary endpoint of combined virologic and biochemical response. Together, the studies are intended to support regulatory filings in the United States and Europe.<\/p>\n
About AZURE-1 and AZURE-4<\/b><\/p>\n
\nAZURE-1 and AZURE-4 are Phase 3 studies that form the basis of Mirum\u2019s U.S. FDA BLA submission for brelovitug in chronic hepatitis delta virus (HDV).<\/p>\n
\nAZURE-1 is evaluating approximately 200 treatment-na\u00efve patients randomized in a 2:2:1 ratio to receive brelovitug 300 mg once weekly, brelovitug 900 mg once monthly, or 24-week delayed therapeutic start. AZURE-4 is evaluating approximately 80 treatment-na\u00efve patients randomized in a 2:1:1 ratio to receive brelovitug 300 mg once weekly, brelovitug 900 mg once monthly, or 12-week delayed therapeutic start. Patients randomized to delayed treatment initiate brelovitug 300 mg once weekly upon completion of the treatment delay in both studies. AZURE-4 is being conducted in partnership with PSI CRO.<\/p>\n
\nThe primary endpoint for both studies is the proportion of patients achieving combined virologic response and ALT normalization at Week 24, consistent with FDA guidance for accelerated approval in HDV. Both studies include open-label extension periods of up to 96 weeks.<\/p>\n
About Mirum Pharmaceuticals<\/b><\/p>\n
\nMirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities.<\/p>\n
\nThe company\u2019s commercial portfolio includes LIVMARLI\u00ae (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM\u00ae (cholic acid) for bile-acid synthesis disorders, and CTEXLI\u00ae (chenodiol) for cerebrotendinous xanthomatosis (CTX). Mirum\u2019s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).<\/p>\n
\nMirum\u2019s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com<\/a> and follow Mirum on Facebook<\/a>, LinkedIn<\/a>, Instagram<\/a> and X<\/a>.<\/p>\n Forward-Looking Statements<\/b><\/p>\n Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things,<\/i>expected timing of topline data for the AZURE studies or BLA submission, the quality of data to be submitted for a brelovitug BLA application in the US, the relationship of antiviral activity as an important endpoint in HDV and the success or approval of any potential regulatory submission for brelovitug. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as \u201canticipate,\u201d \u201cexpected,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cplans,\u201d \u201cintended,\u201d \u201cbelieve,\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum\u2019s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the development of acquired product candidates, including the failure of any expected synergies to be realized; risk and uncertainties arising from the integration of an acquired company, its employees and its assets with Mirum\u2019s business; risks associated with evaluating companies and assets for acquisition, including that the perceived benefits of the acquisition are not realized; risks and uncertainties with the development of investigational medicines generally, including the failure of future studies to generate the same or similar data as prior studies and the potential that estimated prevalences are materially inaccurate; the risks and uncertainties associated with Mirum\u2019s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum\u2019s Annual Report for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 26, 2025, and subsequent filings with the Securities and Exchange Commission, which are available at www.sec.gov<\/a>. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management\u2019s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/i><\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260305481077\/en\/<\/a><\/span><\/p>\n Investor Contact: Media Contact: KEYWORDS:<\/b> California United States North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Health Infectious Diseases Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<\/p>\n
\n<\/b>
Andrew McKibben
\n
ir@mirumpharma.com<\/a><\/p>\n
\n<\/b>
Meredith Kiernan
\n
Media@mirumpharma.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260305481077\/en\/746217\/3\/Mirum_Inline_FullColor_RGB.jpg\")
<\/td>\n<\/tr>\n